Back to MPT Database

Cabotegravir Pellet Implant with Levonorgestrel

The cabotegravir pellet implant with levonorgestrel is a long-acting multipurpose prevention technology implantable product developed by CONRAD combining cabotegravir, for HIV prevention, and levonorgestrel, for contraception, in a biodegradable subdermal pellet system. This product is a low-cost, biodegradable subdermal pellet-type implant system that provides tightly controlled, long-acting sustained release of its payload, is highly tunable, and does not require surgical removal.

*Also referred to as a dual-prevention product by MATRIX

For more information, contact: Gustavo Doncel at doncelgf@evms.edu / conradinnovations@evms.edu

Development Stage:

Preclinical – Early (Pre1)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Systemic - Implant (Subcutaneous)

Mechanism of Action:

Integrase strand-transfer inhibitor; progestrin

Developer:

  • CONRAD

Funding:

  • U.S. Agency for International Development (USAID)

Funding Mechanism:

MATRIX

Past Funding:

Eastern Virginia Medical School (EVMS)

Active Ingredient(s):

  • Cabotegravir
  • Levonorgestrel

Product Indication(s):

  • HIV
  • Pregnancy

Back to MPT Database